StockData
Champions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR) stock

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30245% above fair value
$4.59−0.09 (-1.89%)

Close on Nov 17, 2026Market cap $63.91MP/E –Yield –

Earnings

Champions Oncology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Dec 14, 2026
Q2 FY2027 · estimated, after the close
Revenue, Q1 FY2027
$15.20M
+8.6% on a year earlier
Adjusted EPS, Q1 FY2027
–
$0.02 a year earlier
Latest guidance
Issued
Dec 11, 2024 · 1 item

Quarterly results

Revenue and earnings per share from each of Champions Oncology's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q2 FY2027ended Oct 31, 2026Dec 14, 2026Expected–––––
Q1 FY2027ended Jul 31, 2026Sep 10, 2026after the close$15.20M+8.6%––Release
Q4 FY2026ended Apr 30, 2026Jul 27, 2026after the close$13.80M+12.2%-$0.05$0.01Release
Q3 FY2026ended Jan 31, 2026Mar 12, 2026after the close$16.60M-2.4%-$0.02$0.04Release
Q2 FY2026ended Oct 31, 2025Dec 15, 2025after the close$15.00M+11.1%$0.02$0.06Release
Q1 FY2026ended Jul 31, 2025Sep 15, 2025after the close$14.00M-0.7%-$0.03$0.02Release
Q4 FY2025ended Apr 30, 2025Jul 23, 2025after the close$12.30M-12.1%-$0.13-$0.07Release
Q3 FY2025ended Jan 31, 2025Mar 11, 2025after the close$17.00M+41.7%––Release
Q2 FY2025ended Oct 31, 2024Dec 11, 2024after the close$13.50M+16.4%$0.05$0.05Release
Q1 FY2025ended Jul 31, 2024Sep 11, 2024after the close$14.10M+11.9%$0.09$0.11Release
Q4 FY2024ended Apr 30, 2024Jul 18, 2024after the close$14.00M+6.9%-$0.01$0.01Release
Q3 FY2024ended Jan 31, 2024Mar 12, 2024after the close$12.00M-6.3%-$0.19-$0.16Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Champions Oncology guided for has been reported

Guidance history

Every forecast Champions Oncology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Dec 11, 2024revenue growthFY2025+10% – +15%New
Dec 13, 2022growth targetFY2023+10% – +15%Lowered
Jul 21, 2022top line revenue growthFY2023+20%New
Mar 15, 2022revenue growthFY2022+15% – +20%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Champions Oncology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?